AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30458805 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) and Combined inspiratory and expiratory muscle training in different cycles (CTDC)
Number of subjects: 92
Study 30458805 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT, CTSC, and CTDC
Number of subjects: 92
Study 26494415 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) using interstitial multicatheter brachytherapy
Number of subjects: 1184
Study 26494415 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation with tumour-bed boost
Number of subjects: 1184
Study 26494415 — intervention group
Group type: EXPERIMENTAL
Intervention: APBI
Number of subjects: 1184
Study 26494415 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation
Number of subjects: 1184
Study 23916045 — intervention group
Group type: COMPARATOR
Intervention: Colesevelam (alone or in combination with statins) in pediatric patients
Number of subjects: 0
Study 23916045 — intervention group
Group type: COMPARATOR
Intervention: Colesevelam (added to a maximally tolerated regimen of a statin plus ezetimibe) in adult patients
Number of subjects: 0
Study 20645531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 11
Study 20645531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 18374052 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-study with video
Number of subjects: 3
Study 18374052 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-study with interactive video
Number of subjects: 3
Study 18374052 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-study with interactive video plus expert instruction
Number of subjects: 3
Study 16893273 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management with Cognitive-Behavioral Therapy (CM+CBT)
Number of subjects: 28
Study 16893273 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy alone (CBT)
Number of subjects: 28
Study 12850963 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound device (QUS), Sahara clinical bone sonometer
Number of subjects: 267
Study 12850963 — intervention group
Group type: COMPARATOR
Intervention: Dual energy X‐ray absorptiometry (DEXA)
Number of subjects: 267
Study 10591815 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive patients
Number of subjects: 50
Study 10591815 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 8910179 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ventilation initiated when SpO2 decreased to 90% (Subgroup A)
Number of subjects: 152
Study 8910179 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ventilation initiated when SpO2 decreased to 95% (Subgroup B)
Number of subjects: 152
Study 8910179 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 3-12 years (Group 3)
Number of subjects: 152
Study 8910179 — intervention group
Group type: EXPERIMENTAL
Intervention: All children
Number of subjects: 152
Study 8910179 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 152
Study 1922792 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 21
Study 1922792 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 21
Study 1922792 — intervention group
Group type: COMPARATOR
Intervention: Nondrug conditions
Number of subjects: 21
Study 6412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19
Study 6412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 19
Study 6412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 19
Study 6412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 19
Study 6412157 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 19
Study 4081473 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam treatment
Number of subjects: 112
Study 29509642 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHAG + E2
Number of subjects: 61
Study 29509642 — intervention group
Group type: COMPARATOR
Intervention: GnRHAG + PL
Number of subjects: 61
Study 29509642 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHAG + E2 (no structured exercise)
Number of subjects: 61
Study 29509642 — intervention group
Group type: COMPARATOR
Intervention: GnRHAG + PL (no structured exercise)
Number of subjects: 61
Study 29952487 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplemented group
Number of subjects: 266
Study 29952487 — intervention group
Group type: COMPARATOR
Intervention: No‐iodine supplemented group
Number of subjects: 266
Study 24196554 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured coaching
Number of subjects: 17
Study 24196554 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 17
Study 22208450 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 30
Study 22208450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practices (EBPs) for pain management
Number of subjects: 0
Study 20471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain medication order
Number of subjects: 0
Study 20471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessment
Number of subjects: 0
Study 20471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Review of pain treatment plan
Number of subjects: 0
Study 20471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassessment of moderate or greater pain
Number of subjects: 0
Study 20471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in pain medication
Number of subjects: 0
Study 20471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of analgesic-induced side effects
Number of subjects: 0
Study 20471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of bowel regimen for patients with opioid order
Number of subjects: 0
Study 20471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of nonpharmacological therapies
Number of subjects: 0
Study 20471542 — intervention group
Group type: EXPERIMENTAL
Intervention: Written pain management plans
Number of subjects: 0
Study 17339120 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought suppression under cognitive load
Number of subjects: 0
Study 17339120 — intervention group
Group type: COMPARATOR
Intervention: Concentration on the thought
Number of subjects: 0
Study 15919489 — intervention group
Group type: COMPARATOR
Intervention: Tac/MMF
Number of subjects: 624
Study 15919489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac/0.5SIR
Number of subjects: 624
Study 15919489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac/2SIR
Number of subjects: 624
Study 12752032 — intervention group
Group type: EXPERIMENTAL
Intervention: Hallucination focused Integrative Treatment (HIT)
Number of subjects: 0
Study 12752032 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 0
Study 10333127 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2% sodium bicarbonate
Number of subjects: 0
Study 10333127 — intervention group
Group type: COMPARATOR
Intervention: 4.5% human albumin
Number of subjects: 0
Study 8604439 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic study (EPS)
Number of subjects: 0
Study 8604439 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring (HM)
Number of subjects: 0
Study 8604439 — intervention group
Group type: EXPERIMENTAL
Intervention: EPS combined with HM
Number of subjects: 0
Study 8604439 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted drug efficacy
Number of subjects: 0
Study 8604439 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 1932651 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinyl‐linked gelatin
Number of subjects: 105
Study 1932651 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea‐linked gelatin
Number of subjects: 105
Study 1932651 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 105
Study 6218104 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (2 g intravenously before surgery and every eight hours until the fifth postoperative day)
Number of subjects: 100
Study 6218104 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mezlocillin)
Number of subjects: 100
Study 6218104 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 100
Study 31356571 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based pain management strategies implemented after the audit
Number of subjects: 30
Study 31356571 — intervention group
Group type: COMPARATOR
Intervention: Baseline audit before implementation
Number of subjects: 30
Study 30016473 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral health intervention
Number of subjects: 187
Study 30016473 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual PC (UC+)
Number of subjects: 187
Study 26878838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multidisciplinary pulmonary rehabilitation programme (6-week duration)
Number of subjects: 103
Study 26878838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 103
Study 26878838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multidisciplinary pulmonary rehabilitation programme
Number of subjects: 103
Study 26878838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 25193157 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 25 micrograms every 2 hours for a maximum of 12 doses or until active labor commences
Number of subjects: 602
Study 25193157 — intervention group
Group type: COMPARATOR
Intervention: Transcervical Foley catheter (silicone, size 18 F with 30 ml balloon) until active labor starts, the Foley catheter falls out, or 12 hours have elapsed
Number of subjects: 602
Study 22869830 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucalyptus honey
Number of subjects: 300
Study 22869830 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus honey
Number of subjects: 300
Study 22869830 — intervention group
Group type: EXPERIMENTAL
Intervention: Labiatae honey
Number of subjects: 300
Study 22869830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (silan date extract)
Number of subjects: 300
Study 19783324 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Number of subjects: 132
Study 19783324 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring alone (blinded capnography)
Number of subjects: 132
Study 17413103 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g fat/d (2.4 g fat/meal)
Number of subjects: 116
Study 17413103 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g fat/d (5 g fat/meal)
Number of subjects: 116
Study 17413103 — intervention group
Group type: EXPERIMENTAL
Intervention: 29 g fat/d (10 g fat/meal)
Number of subjects: 116
Study 15621801 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² once a week)
Number of subjects: 30
Study 15621801 — intervention group
Group type: COMPARATOR
Intervention: Non-rituximab interventions (observation, immunosuppression reduction, surgery, chemotherapy, radiation or a combination)
Number of subjects: 30
Study 15621801 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab therapy
Number of subjects: 30
Study 15621801 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to treatment
Number of subjects: 30
Study 15621801 — intervention group
Group type: EXPERIMENTAL
Intervention: CD20 positive status
Number of subjects: 30
Study 15621801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low international prognostic index (IPI)
Number of subjects: 30
Study 15621801 — intervention group
Group type: EXPERIMENTAL
Intervention: Good performance status
Number of subjects: 30
Study 15621801 — intervention group
Group type: EXPERIMENTAL
Intervention: CD20-positive status
Number of subjects: 30
Study 15621801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low performance status
Number of subjects: 30
Study 15621801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low IPI and rituximab therapy
Number of subjects: 30
Study 11172269 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression therapy delivered after elective hip surgery
Number of subjects: 79
Study 11172269 — intervention group
Group type: COMPARATOR
Intervention: Nursing education program
Number of subjects: 79
Study 9692584 — intervention group
Group type: EXPERIMENTAL
Intervention: Open antireflux surgery
Number of subjects: 178
Study 7842828 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin plus netilmicin 5 mg/kg
Number of subjects: 40
Study 7842828 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin plus pefloxacine 10 mg/kg
Number of subjects: 40
Study 3136820 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisdine instillations
Number of subjects: 18
Study 3136820 — intervention group
Group type: COMPARATOR
Intervention: kanamycin-colistin instillations
Number of subjects: 18
Study 31227453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS) applied daily for 3 weeks
Number of subjects: 21
Study 31227453 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LIPUS treatment)
Number of subjects: 21
Study 28304224 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg every 2 weeks or 420 mg monthly)
Number of subjects: 27564
Study 28304224 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564
Study 28304224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27564
Study 25376374 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling RIC transplant
Number of subjects: 0
Study 25376374 — intervention group
Group type: COMPARATOR
Intervention: MUD RIC transplant
Number of subjects: 0
Study 25376374 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 25376374 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 35-44 years with sibling RIC transplant
Number of subjects: 0
Study 23880306 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART initiation regardless of CD4 count
Number of subjects: 34000
Study 23880306 — intervention group
Group type: COMPARATOR
Intervention: ART according to national treatment eligibility guidelines (CD4 <350 cells/μL, WHO stage 3 or 4 disease, or multidrug/extensively drug-resistant tuberculosis)
Number of subjects: 34000
Study 23880306 — intervention group
Group type: COMPARATOR
Intervention: ART according to national treatment eligibility guidelines
Number of subjects: 34000
Study 21714857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (1 μg/kg/min continuous infusion during CPB)
Number of subjects: 80
Study 21714857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during CPB)
Number of subjects: 80
Study 19379152 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoproten apheresis
Number of subjects: 20
Study 19379152 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 18349477 — intervention group
Group type: COMPARATOR
Intervention: Quota-based walking program (8-week duration)
Number of subjects: 3
Study 15241887 — intervention group
Group type: EXPERIMENTAL
Intervention: Shampoo containing a standardized extract of Solanum chrysotrichum (applied every third day for 4 weeks)
Number of subjects: 103
Study 15241887 — intervention group
Group type: COMPARATOR
Intervention: 2% ketoconazole
Number of subjects: 103
Study 11263600 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 7159
Study 11263600 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 7159
Study 11263600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 3-vessel disease (3VD) undergoing PCI
Number of subjects: 7159
Study 11263600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 2-vessel disease (2VD) undergoing PCI
Number of subjects: 7159
Study 9135945 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (0.05 IU/kg)
Number of subjects: 40
Study 9135945 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 9135945 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (correctly informed)
Number of subjects: 40
Study 9135945 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (expectation without knowledge)
Number of subjects: 40
Study 9135945 — intervention group
Group type: COMPARATOR
Intervention: Saline (expectation without knowledge)
Number of subjects: 40
Study 7870881 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 40
Study 7870881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3777587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC) given as a single dose one hour after SRT dosing (Group 1)
Number of subjects: 20
Study 3777587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC) given in four doses at three-hour intervals starting one hour after SRT dosing (Group 2)
Number of subjects: 20
Study 3777587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC) given in four doses at three-hour intervals starting three hours after SRT dosing (Group 3)
Number of subjects: 20
Study 3777587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC) given in three doses at three-hour intervals starting six hours after SRT dosing (Group 4)
Number of subjects: 20
Study 30987860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal ctDCS
Number of subjects: 48
Study 30987860 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal ctDCS
Number of subjects: 48
Study 30987860 — intervention group
Group type: COMPARATOR
Intervention: Sham ctDCS
Number of subjects: 48
Study 28757287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load lifting exercise (HLL)
Number of subjects: 66
Study 28757287 — intervention group
Group type: COMPARATOR
Intervention: Low-load motor control exercises (LMC)
Number of subjects: 66
Study 28757287 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup LOW lumbar lordosis (LOWlu)
Number of subjects: 66
Study 28757287 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup HIGH sacral angle (HIGHsa)
Number of subjects: 66
Study 26689566 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237) 50 mg enteric-coated tablet under fed conditions
Number of subjects: 24
Study 26689566 — intervention group
Group type: COMPARATOR
Intervention: Alisertib (MLN8237) 50 mg enteric-coated tablet under fasted conditions
Number of subjects: 24
Study 26689566 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237) 50 mg enteric-coated tablet
Number of subjects: 24
Study 24594247 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-recumbent positioning
Number of subjects: 34
Study 24594247 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 34
Study 24594247 — intervention group
Group type: COMPARATOR
Intervention: Control (Supine position)
Number of subjects: 34
Study 22929268 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe metopic synostosis (endocranial bifrontal angle 100 to 124 degrees)
Number of subjects: 35
Study 22929268 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate metopic synostosis (endocranial bifrontal angle 124 to 148 degrees)
Number of subjects: 35
Study 22929268 — intervention group
Group type: COMPARATOR
Intervention: Control group (endocranial bifrontal angle 134 to 160 degrees)
Number of subjects: 35
Study 22929268 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe metopic synostosis
Number of subjects: 35
Study 20339875 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical closure of trocar site using tip hole needle and redirecting suture hook
Number of subjects: 120
Study 18442879 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 50
Study 18442879 — intervention group
Group type: COMPARATOR
Intervention: Oral risperidone
Number of subjects: 50
Study 16163920 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SUP (supine position)
Number of subjects: 26
Study 16163920 — intervention group
Group type: COMPARATOR
Intervention: Group LAT (lateral decubitus position)
Number of subjects: 26
Study 12673167 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective instillation of 131I-Lipiodol to the proper hepatic artery (SEL group)
Number of subjects: 24
Study 12673167 — intervention group
Group type: COMPARATOR
Intervention: Hyperselective instillation of 131I-Lipiodol in the right or left hepatic artery (HYP-SEL group)
Number of subjects: 24
Study 12673167 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SEL and HYP-SEL)
Number of subjects: 24
Study 10545552 — intervention group
Group type: EXPERIMENTAL
Intervention: iNO at 2 ppm
Number of subjects: 38
Study 10545552 — intervention group
Group type: EXPERIMENTAL
Intervention: iNO at 20 ppm (after initial treatment with 0 ppm)
Number of subjects: 38
Study 10545552 — intervention group
Group type: EXPERIMENTAL
Intervention: iNO at 20 ppm (after initial treatment with 2 ppm)
Number of subjects: 38
Study 10545552 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 ppm)
Number of subjects: 38
Study 10545552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose iNO group (2 ppm)
Number of subjects: 38
Study 8340472 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (3 daily 15-minute massages for 10 days)
Number of subjects: 93
Study 8340472 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 93
Study 8340472 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 93
Study 3724994 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical shocks administered to the right forearm at four intensities
Number of subjects: 44
Study 29850955 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-cm surgical margin
Number of subjects: 400
Study 29850955 — intervention group
Group type: COMPARATOR
Intervention: 2-cm surgical margin
Number of subjects: 400
Study 29850955 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400